Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1505 participants
OBSERVATIONAL
2024-01-01
2024-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study is a retrospective analysis focusing on evaluating survival rates, identifying prognostic factors, and formulating treatment recommendations for patients with G-NEC. By analyzing real-world clinical data, we aim to better understand the factors that influence patient outcomes and to develop evidence-based strategies for improving survival. Our goal is to provide clinicians with valuable insights and tools to make more informed treatment decisions, ultimately enhancing the quality of care and outcomes for patients with this challenging disease.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Gastric Neuroendocrine Carcinoma (G-NEC) Patients
This study focuses on patients diagnosed with gastric neuroendocrine carcinoma (G-NEC) who have undergone radical surgery. The cohort includes adult patients (≥18 years) treated at 38 tertiary hospitals in China between January 2006 and December 2020. Patients are divided into three groups based on their postoperative adjuvant treatment: no adjuvant chemotherapy, etoposide and platinum derivatives-based chemotherapy, and fluorouracil-based chemotherapy. The study aims to develop and validate a machine learning-based decision support model to optimize individualized adjuvant therapy strategies for G-NEC patients, with the primary outcome being disease-free survival (DFS).
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* (2) pathology confirmed NEC or mixed adenoneuroendocrine carcinoma (MANEC).
Exclusion Criteria
* (2) treatment with endoscopic submucosal dissection or endoscopic mucosal resection or thoracotomy;
* (3) incomplete clinical data (including pathological, adjuvant chemotherapy, and follow-up information);
* (4) receipt of alternative adjuvant treatment regimens;
* (5) death within 30 days postoperatively.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chang-Ming Huang, Prof.
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chang-Ming Huang, Prof.
Prof.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fujian Medical University
Fuzhou, Fujian, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024GNEC
Identifier Type: -
Identifier Source: org_study_id